Sullivan & Cromwell and Ropes & Gray advised on Agilent Technologies’ $950 million acquisition of Biocare Medical.
Agilent Technologies, a global leader in analytical and clinical laboratory technologies, has agreed to acquire Biocare Medical in an all-cash transaction valued at $950 million.
The acquisition strengthens Agilent’s immunohistochemistry offering and expands its ability to serve a wide range of pathology laboratories across clinical and research settings.
Biocare Medical is a recognized leader in immunohistochemistry (IHC) and molecular pathology solutions, with more than 300 specialized antibodies and a robust R&D capability.
Sullivan & Cromwell advised Agilent Technologies. The deal team was led by Pete Jones and Greg Travers.
Ropes & Gray advised Biocare Medical on the transaction.
The team included Private Equity Partners Tim Castelli and Andrew Pomranke, Litigation & Enforcement Partners Zak Goodwin and Ruchit Patel, Tax Partner Elaine Murphy, Employment. Partner Jen Cormier, and Private Equity Counsel Raxit Shah.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
